Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

EVGN - Evogene Ltd.


IEX Last Trade
1.73
0   0%

Share volume: 1,072
Last Updated: Fri 27 Dec 2024 04:38:37 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%

$1.73
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
5%
Profitability 0%
Dept financing 5%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
25.19%
1 Month
0.18%
3 Months
-33.98%
6 Months
144.93%
1 Year
100.12%
2 Year
150.30%
Key data
Stock price
$1.73
P/E Ratio 
0.00
DAY RANGE
$1.51 - $1.72
EPS 
$0.00
52 WEEK RANGE
$0.59 - $6.30
52 WEEK CHANGE
$101.19
MARKET CAP 
16.642 M
YIELD 
N/A
SHARES OUTSTANDING 
5.058 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/21/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$76,183
AVERAGE 30 VOLUME 
$63,333
Company detail
CEO: Ofer Haviv
Region: US
Website: evogene.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Evogene Ltd. focuses on product discovery and development in multiple life-science based industries, including human health and agriculture. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer.

Recent news